Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1624 1627
This examiner grants 76% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18533710 | SOLID FORMS OF (3R)-N-[2-CYANO-4-FLUORO-3-(3-METHYL-4-OXO-QUINAZOLIN-6-YL)OXY-PHENYL]-3-FLUORO-PYRROLIDINE-1-SULFONAMIDE | Non-Final OA | Hoffmann-La Roche Inc. |
| 18076274 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | Non-Final OA | Hoffmann-La Roche Inc. |
| 17794314 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND THERAPEUTIC PHARMACEUTIC COMPOSITION COMPRISING SAME | Non-Final OA | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY |
| 17995388 | CRYSTALLINE FORMS OF 4-[(7-CHLORO-2-METHOXYBENZO[B][1,5]NAPHTHYRIDIN-10-YL)AMINO]-2,6-BIS(PYRROLIDIN-1-YLMETHYL)PHENOL AND SALTS THEREOF | Final Rejection | Merck Patent GmbH |
| 17757572 | NOVEL USES | Non-Final OA | Intra-Cellular Therapies, Inc. |
| 18302313 | Heterocyclic Compounds as RET Kinase Inhibitors | Non-Final OA | Cancer Research Technology Limited |
| 18563554 | 1,2-DIHYDROQUINOLINE-2-ONES FOR THEIR USE IN THE TREATMENT OF LIMB-GIRDLE MUSCULAR DYSTROPHY | Non-Final OA | ADMINISTRACIÓN GENERAL DE LA COMUNIDAD AUTÓNOMA DE EUSKADI |
| 18556196 | IL4I1 INHIBITORS AND METHODS OF USE | Non-Final OA | MSD R&D (CHINA) CO., LTD. |
| 18556178 | GPR35 Agonist Compounds | Non-Final OA | NXERA PHARMA UK LIMITED |
| 17923754 | Uses and Formulations of Cannabinoids | Non-Final OA | ADD Advanced Drug Delivery Technologies Ltd. |
| 18554211 | SUBSTITUTED SULFONAMIDE-CHROMAN COMPOUNDS, AND PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | Non-Final OA | Sumitomo Pharma America, Inc. |
| 18278715 | SUBSTITUTED PYRIDINE-2,4-DIONE DERIVATIVES | Non-Final OA | SOTER BIOPHARMA PTE. LTD. |
| 18015261 | ATX INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Final Rejection | SUZHOU ARK BIOPHARMACEUTICAL CO., LTD. |
| 17995327 | ACTIVE SUBSTANCES FOR MEDICAL USE | Final Rejection | INFLAMED PHARMA GMBH |
| 17592779 | COMPOUNDS AND METHOD FOR TREATING CYTOKINE RELEASE SYNDROME | Final Rejection | Rigel Pharmaceuticals, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy